Impact of comorbid asthma on severity of coronavirus disease (COVID-19)

Sci Rep. 2020 Dec 11;10(1):21805. doi: 10.1038/s41598-020-77791-8.

Abstract

The severity of the coronavirus disease (COVID-19) is associated with various comorbidities. However, no studies have yet demonstrated the potential risk of respiratory failure and mortality in COVID-19 patients with pre-existing asthma. We selected 7272 adult COVID-19 patients from the Korean Health Insurance Review and Assessment COVID-19 database for this nationwide retrospective cohort study. Among these, 686 patients with asthma were assessed by their severities and evaluated by the clinical outcome of COVID-19 compared to patients without asthma. Of 7272 adult COVID-19 patients, 686 with asthma and 6586 without asthma were compared. Asthma was not a significant risk factor for respiratory failure or mortality among all COVID-19 patients (odds ratio [OR] = 0.99, P = 0.997 and OR = 1.06, P = 0.759) after adjusting for age, sex, and the Charlson comorbidity score. However, a history of acute exacerbation (OR = 2.63, P = 0.043) was significant risk factors for death among COVID-19 patients with asthma. Asthma is not a risk factor for poor prognosis of COVID-19. However, asthma patients who had any experience of acute exacerbation in the previous year before COVID-19 showed higher COVID-19-related mortality, especially in case of old age and male sex.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Asthma / mortality*
  • Asthma / therapy
  • COVID-19 / mortality*
  • COVID-19 / therapy
  • Comorbidity
  • Female
  • Humans
  • Male
  • Middle Aged
  • Republic of Korea / epidemiology
  • Respiratory Insufficiency / mortality*
  • Respiratory Insufficiency / therapy
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2*